Source: Zolmax News

Leap Therapeutics: Leap Therapeutics Inc (NASDAQ:LPTX) Expected to Post Earnings of -$0.26 Per Share

Equities research analysts expect Leap Therapeutics Inc (NASDAQ:LPTX) to report ($0.26) earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Leap Therapeutics' earnings. The highest EPS estimate is ($0.13) and the lowest is ($0.47). Leap Therapeutics reported earnings per share of ($0.37) during the same quarter [...]

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Employees
Chris Mirabelli's photo - CEO of Leap Therapeutics

CEO

Chris Mirabelli

CEO Approval Rating

73/100

Leap Therapeutics researches, develops and commercializes monoclonal antibodies that enable immune system to identify and attack cancer cells. Read more